Published online Sep 6, 2020. doi: 10.12998/wjcc.v8.i17.3743
Peer-review started: April 14, 2020
First decision: May 15, 2020
Revised: May 25, 2020
Accepted: August 12, 2020
Article in press: August 12, 2020
Published online: September 6, 2020
Processing time: 142 Days and 22.4 Hours
Pancreatic cancer has the characteristics of late detection, early metastasis, rapid progression, and poor prognosis.
Application of 125I seeds in the treatment of pancreatic cancer.
To summarize a single center experience with 125I seed implantation in the treatment of locally advanced pancreatic cancer.
The demographics and perioperative outcomes of a consecutive series of patients who underwent 125I seed implantation to treat locally advanced pancreatic cancer were retrospectively analyzed. According to the results of preoperative computed tomography or magnetic resonance imaging, the treatment planning system was used to determine the area and number of 125I seeds implanted.
Among the 50 patients, there were 29 males and 21 females, with a mean age of 56.9 ± 9.8 years. The main reason for the failure of radical resection was superior mesenteric artery invasion, followed by superior mesenteric vein invasion. Twenty-one patients underwent palliative surgery and postoperative pain relief occurred in 40 patients. The estimated blood loss in operation was 107.4 ± 115.3 mL and none of the patient received blood transfusion. After operation, 26 patients received chemotherapy and 24 patients did not. The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not. The mean OS of patients of the chemotherapy group and non-chemotherapy group was 14 mo and 11 mo, respectively.
Our experience shows that 125I seed implantation is not only effective for unresectable local advanced pancreatic cancer patients, but can also reduce the clinical symptoms and prolong the relative survival time of those patients.
The diversification of cancer treatments has contributed to its survival rate.